On 26 June 2020, orphan designation EU/3/20/2288 was granted by the European Commission to Granzer Regulatory Consulting & Services, Germany, for magrolimab for the treatment of myelodysplastic syndromes.
The sponsorship was transferred to Gilead Sciences Ireland UC, Ireland, in September 2020.
|Disease / condition||
Treatment of myelodysplastic syndromes
|Date of first decision||
|EU designation number||
Review of designation
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.